UCB has agreed to acquire Ra Pharmaceuticals for $2.1 billion in cash. The deal enables UCB to offer new treatment opportunities for several rare diseases in neurology and immunology. “Ra Pharma is an excellent strategic fit addressing multiple areas of UCB’s patient value growth strategy,” UCB’s Chief Executive Officer Jean-Christophe Tellier said in a joint statement. Tellier added that the acquisition would generate six potential product launches in the next five years, strengthening the company’s neurology and immunology franchises with late and early-stage pipeline projects. Learn More